WP
PFE icon

Westmount Partners’s Pfizer PFE Stock Holding History

Westmount Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$255K Sell
10,594
-2,004
-16% -$52.4K 0.06% 229
2026
Q1 		$354K Buy
12,598
+2,196
+21% +$58.5K 0.09% 186
2025
Q4 		$259K Buy
10,402
+1,576
+18% +$39.7K 0.06% 215
2025
Q3 		$240K Sell
8,826
-5,165
-37% -$127K 0.06% 222
2025
Q2 		$339K Sell
13,991
-907
-6% -$21.2K 0.09% 171
2025
Q1 		$378K Buy
14,898
+7
+0% +$183 0.12% 152
2024
Q4 		$395K Sell
14,891
-1,643
-10% -$44.6K 0.12% 136
2024
Q3 		$478K Sell
16,534
-728
-4% -$21.2K 0.14% 119
2024
Q2 		$487K Sell
17,262
-1,313
-7% -$36.1K 0.16% 113
2024
Q1 		$515K Buy
18,575
+1,658
+10% +$46K 0.19% 110
2023
Q4 		$487K Sell
16,917
-1,586
-9% -$47.9K 0.2% 105
2023
Q3 		$614K Sell
18,503
-799
-4% -$28.3K 0.27% 84
2023
Q2 		$708K Buy
19,302
+46
+0.2% +$1.79K 0.31% 71
2023
Q1 		$786K Sell
19,256
-1,250
-6% -$54K 0.36% 61
2022
Q4 		$1.05M Buy
+20,506
New +$983K 0.55% 38

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Westmount Partners's PFE Position: Q2 2026 in Review

Westmount Partners reduced its Pfizer (PFE) stake by 16% in Q2 2026, selling an estimated $52.4K and leaving 10,594 shares worth $255K. The position accounts for 0.06% of the portfolio, ranked #229.

Westmount Partners first reported a position in PFE in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.05M in Q4 2022. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Westmount Partners held 10,594 shares of Pfizer worth $255K as of Q2 2026.
  • Westmount Partners sold 2,004 Pfizer shares in Q2 2026, an estimated $52.4K.
  • Pfizer made up 0.06% of Westmount Partners's portfolio in Q2 2026, its #229 holding.
  • Westmount Partners first reported a position in Pfizer in Q4 2022 and has held it in 15 quarters since.
  • Westmount Partners's Pfizer position peaked at $1.05M in Q4 2022.
  • 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Westmount Partners's 13F filing for Q2 2026, filed 7 Jul 2026.